Compare Aehr Test Systems (AEHR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs TG Therapeutics Inc — how do they compare? Aehr Test Systems trades at $66.86 (market cap $2.11B), while TG Therapeutics Inc trades at $56.42 (market cap $8.89B). The key difference: TG Therapeutics Inc is far larger — about 4.2× Aehr Test Systems's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Aehr Test Systems nearer its low. Which is the better fit depends on your goals.
| AEHR | TGTX | |
|---|---|---|
Market Cap | $2.11B | $8.89B |
Sector | Technology | Health |
52-Week High | $116.58 | $58.06 |
52-Week Low | $13.29 | $26.39 |
Enterprise Value | $2.08B | $9.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
